Leonteq Securities AG Exchange Traded Product 2025-open end

Leonteq Securities AG Exchange Traded Product 2025-open end is offered by Leonteq, a leading player in the field of passive investments.

The total expense ratio of Leonteq Securities AG Exchange Traded Product 2025-open end is 0.6%, which means that investors pay 60 CHF per 10,000 CHF in investment capital annually.

The ETF is listed in CHF.

European investors may incur additional costs for currency exchange and transaction fees.

No, Leonteq Securities AG Exchange Traded Product 2025-open end does not comply with the EU UCITS investor protection directives.

Leonteq Securities AG Exchange Traded Product 2025-open end tracks the performance of the Saxo Healthcare Innovation Select Equity Index - CHF - Benchmark TR Net.

Leonteq Securities AG Exchange Traded Product 2025-open end is domiciled in CH.

The fund was launched on 9/30/2025.

The Leonteq Securities AG Exchange Traded Product 2025-open end mainly invests in Healthcare companies.

The NAV of Leonteq Securities AG Exchange Traded Product 2025-open end amounts to 15.3 M CHF.

Investments can be made through brokers or financial institutions that provide access to trading ETFs.

The ETF is traded on the stock exchange, similar to stocks.

Yes, the ETF can be held in a regular securities account.

The ETF is suitable for both short-term and long-term investment strategies, depending on the investor's goals.

The ETF is valued on a daily stock exchange basis.

Information on dividends should be requested from the provider's website or your broker.

The risks include market fluctuations, currency risks, and the risk associated with smaller companies.

The ETF is obligated to report regularly and transparently on its investments.

The performance can be viewed on Eulerpool or directly on the provider's website.

Further information can be found on the official website of the provider.